Postprandial glucose reduction (PPG reduction)

Postprandial glucose reduction is a clinical therapeutic objective and a physiological process rather than a discrete molecular target such as a receptor or enzyme. It refers to the attenuation of the rise in blood glucose levels that occurs after food consumption, a phenomenon central to maintaining glucose homeostasis and preventing complications in patients with diabetes mellitus [2, 14]. Elevated postprandial glucose (PPG) is a major contributor to overall glycated hemoglobin (HbA1c) levels and is independently associated with increased oxidative stress, endothelial dysfunction, and a higher risk of cardiovascular events [8, 11]. Although it is not a single protein, PPG reduction is the primary pharmacodynamic effect of several drug classes targeting different biological pathways: alpha-glucosidase inhibitors slow intestinal carbohydrate digestion; GLP-1 receptor agonists and DPP-4 inhibitors enhance the glucose-dependent incretin response; and rapid-acting insulin analogues provide mealtime glycemic coverage [1, 5, 12]. Successful management of post-meal excursions is essential for comprehensive glycemic control and reducing the long-term burden of metabolic disease [14].

Other names

Postprandial glucose loweringPost-meal glucose reductionPPG controlPostprandial glycemic controlReduction of postprandial glycemia

Postprandial glucose reduction is achieved through multiple pharmacological mechanisms, including the inhibition of alpha-glucosidase enzymes to delay carbohydrate absorption, activation of GLP-1 receptors to enhance glucose-dependent insulin secretion and delay gastric emptying, and the administration of rapid-acting insulin analogues to facilitate cellular glucose uptake.